Sign in

Private company

CureVac N.V.

CureVac N.V. is a pharmaceutical preparations company.1

Last updated Oct 21, 2026.

Overview

162.2MNet income, fiscal 20242
  • IndustryPharmaceutical Preparations1
  • HeadquartersP71
  • Incorporated inNetherlands3
  • Business addressFriedrich-Miescher-Strasse 15, Tubingen, 720763
  • Filer categoryAccelerated filer3

See how the biggest companies compare on our leaderboards

On April 7, 2020, CureVac B.V. was incorporated under the laws of the Netherlands and became the holding company of CureVac AG in connection with our initial public offering on August 14, 2020, as part of a corporate reorganization (the “Corporate Reorganization”), in which the legal form of CureVac B.V. was converted from a Dutch private company with limited liability ( besloten vennootschap met beperkte aansprakelijkheid ) to a Dutch public company ( naamloze vennootschap ), and the articles of association of CureVac N.V. became effective. Following the Corporate Reorganization, CureVac N.V. became the holding company of CureVac AG. On September 26, 2022, CureVac AG entered into a plan of merger with CureVac Beteiligungsverwaltungs AG, with CureVac SE as the surviving entity and both CureVac AG and CureVac Beteiligungsverwaltungs AG as disappearing entities. The historical consolidated…4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2024

23.3%Return on equity2
$87.5MFree cash flow2

Financial statements

Operating income56782$177.7M in 2024
-$600.0M-$400.0M-$200.0M0$200.0M2018: -$72.8M-$72.8M20182019: -$99.5M-$99.5M2019+37%2020: -$109.8M-$109.8M2020+10%2021: -$412.3M-$412.3M2021+275%2022: -$249.5M-$249.5M2022−39%2023: -$274.2M-$274.2M2023+10%2024: $177.7M$177.7M2024
Net income56782$162.2M in 2024
-$600.0M-$400.0M-$200.0M0$200.0M2018: -$71.2M-$71.2M20182019: -$99.9M-$99.9M2019+40%2020: -$129.1M-$129.1M2020+29%2021: -$411.7M-$411.7M2021+219%2022: -$249.0M-$249.0M2022−40%2023: -$260.2M-$260.2M2023+4%2024: $162.2M$162.2M2024
Fiscal year20172018201920202021202220232024
Cost of revenue238.2M EUR8184.0M EUR2124.4M EUR2105.8M EUR2
Research and development815.9M EUR862.5M EUR2115.7M EUR2153.0M EUR2
Operating income-72.8M EUR5-99.5M EUR6-109.8M EUR7-412.3M EUR8-249.5M EUR2-274.2M EUR2177.7M EUR2
Interest10.3M EUR83.7M EUR22.5M EUR2829.0K EUR2
Income before tax-412.5M EUR8-249.2M EUR2-260.0M EUR2190.9M EUR2
Income tax-782.0K EUR8-126.0K EUR2198.0K EUR228.7M EUR2
Net income-71.2M EUR5-99.9M EUR6-129.1M EUR7-411.7M EUR8-249.0M EUR2-260.2M EUR2162.2M EUR2
Earnings per share1 EUR/shares5-1 EUR/shares6-1 EUR/shares7-2 EUR/shares8-1 EUR/shares2-1 EUR/shares21 EUR/shares2
Earnings per share (diluted)-1 EUR/shares6-1 EUR/shares7-2 EUR/shares8-1 EUR/shares2-1 EUR/shares21 EUR/shares2
Shares (weighted, basic)186.0M shares8189.1M shares2220.9M shares2224.4M shares2
Shares (weighted, diluted)225.3M shares2

Compare CureVac N.V. with another company

Corporate structure

CureVac N.V. sits at the top of its group. 1 entity on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of CureVac N.V.

  • KfW Filed SCHEDULE 13D/A on CureVac N.V., latest Dec 12, 2025 (6 filings since Oct 18, 2021)
  • Mathias Hothum Filed SCHEDULE 13D/A on CureVac N.V., latest Dec 12, 2025 (4 filings since May 5, 2022)
  • dievini Hopp BioTech holding GmbH & Co KG Filed SCHEDULE 13D/A on CureVac N.V., latest Dec 12, 2025 (9 filings since Oct 15, 2021)
  • GSK Filed SCHEDULE 13D/A on CureVac N.V., latest Dec 5, 2025 (3 filings since Feb 6, 2024)
  • RA CAPITAL MANAGEMENT, L.P. Filed SC 13G/A on CureVac N.V., latest Feb 14, 2024 (2 filings since Mar 27, 2023)
  • Bohlen Und Halback Friedrich Von Filed SC 13D/A on CureVac N.V., latest Feb 24, 2023 (4 filings since May 5, 2022)
  • Christof Hettich Filed SC 13D/A on CureVac N.V., latest Feb 24, 2023 (4 filings since May 5, 2022)
  • CureVac N.V. P7

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What CureVac N.V. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, net204.9M EUR2 Dec 31, 2024236.8M EUR2 Dec 31, 2023−13.4%
Operating-lease assets (leased space)39.7M EUR2 Dec 31, 202441.8M EUR2 Dec 31, 2023−5.1%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents481.7M EUR2 Dec 31, 2024402.5M EUR2 Dec 31, 2023+19.7%

Intangibles and goodwill

ItemLatestA year beforeChange
Intangible assets, net (excluding goodwill)25.2M EUR2 Dec 31, 202428.3M EUR2 Dec 31, 2023−11.3%

Inventory

ItemLatestA year beforeChange
Inventory, total541.0K EUR2 Dec 31, 202424.8M EUR2 Dec 31, 2023−97.8%

Former names

  • CureVac B.V.Apr 29, 2020 to Aug 14, 20203

Filings

170 filings to the SEC since October 2021: 5 annual reports, 32 large holders, 133 other. The latest 20:

  1. Jan 16, 202615-12G EDGAR
  2. Jan 7, 2026S-8 POS EDGAR
  3. Jan 6, 20266-K EDGAR
  4. Dec 18, 2025SC 14D9/A EDGAR
  5. Dec 12, 2025SCHEDULE 13D/A EDGAR
  6. Dec 12, 2025SCHEDULE 13D/A EDGAR
  7. Dec 12, 2025SCHEDULE 13D/A EDGAR
  8. Dec 5, 2025SCHEDULE 13D/A EDGAR
  9. Dec 5, 2025SC 14D9/A EDGAR
  10. Nov 26, 2025SC 14D9/A EDGAR
  11. Nov 26, 20256-K EDGAR
  12. Nov 25, 2025SC 14D9/A EDGAR
  13. Nov 24, 2025SC 14D9/A EDGAR
  14. Nov 24, 20256-K EDGAR
  15. Oct 27, 20256-K EDGAR
  16. Oct 23, 2025SC 14D9/A EDGAR
  17. Oct 22, 2025SC 14D9/A EDGAR
  18. Oct 21, 2025SC 14D9 EDGAR
  19. Aug 15, 20256-K EDGAR
  20. Aug 13, 2025SCHEDULE 13D EDGAR

The 170 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How CureVac N.V. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARCureVac N.V.1
  • CIK0001809122
  • Filer statusAccelerated filer not an emerging growth company; not a shell company4
  • Incorporated inNetherlands4
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business addressFriedrich-Miescher-Strasse 15, Tubingen, Baden-Wurttemberg 72076, Germany1
  • Phone49 7071 9883 01
  • Shares outstanding224,338,257 shares as of Dec 31, 20244
  • AuditorKPMG AG Wirtschaftsprüfungsgesellschaft, Stuttgart, Germany PCAOB ID 1021; it also attests to the company’s internal control over financial reporting4
  • On EDGAR sinceApr 29, 20201
  • Filings274 in all: 6-K (151), SC 13D/A (20), 425 (16), 144 (12), CORRESP (7), SC 14D9/A (7), SCHEDULE 13D/A (6), UPLOAD (6)1
    All 33 form types

    20-F (5), SC 13D (5), SC TO-T/A (4), 424B4 (3), DRSLTR (3), F-1/A (3), DRS (2), DRS/A (2), EFFECT (2), F-1 (2), S-8 POS (2), SC 13G (2), SC 13G/A (2), 15-12G (1), 20-F/A (1), 25-NSE (1), 424B5 (1), 8-A12B (1), CERT (1), F-3ASR (1), S-8 (1), SC 14D9 (1), SC TO-T (1), SC14D9C (1), SCHEDULE 13D (1)

  • Latest filingsAnnual report (20-F) Apr 11, 2025

Securities registered for trading

ClassSymbolExchange
Common shares, par value €0.12 per shareCVACNASDAQ

From the cover page of the 20-F filed Apr 11, 2025 (Section 12(b) of the Exchange Act).4

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15